My approach to drug development is defined by three core values:

Rigor & Reproducibility

I apply disciplined experimental design, SOP-driven execution, and high-quality data standards to generate repeatable, decision-ready evidence.

Safety-by-Design

I integrate safety and risk assessment early—building programs with a clear path to IND-enabling requirements and first-in-human readiness.

Efficient Translation

I use milestone-based planning and defined go/no-go criteria to move programs efficiently from discovery through preclinical development and into Phase I.